AI
Tuesday, April 28, 2009 1:28:44 PM
Vertex (VTRX) has set a new benchmark for the treatment of HCV. Its HCV candidate, Telaprevir, demonstrated significant reduction in viral load with 4.4-log reduction in viral load compared to 1-2 log reduction seen in other standard of care interferon therapy.
We believe that this data sets the bar very high, and we are unsure whether Anadys (ANDS) can reach it. Currently, Telaprevir is undergoing phase III studies. Valeant’s (VRX) Taribavirin (previously known as Viramidine) is in advanced clinical development.
http://www.zacks.com/stock/news/19571/Anadys:+Too+Early+for+HCV+Drug
its counter part ANDS doing poorly
We believe that this data sets the bar very high, and we are unsure whether Anadys (ANDS) can reach it. Currently, Telaprevir is undergoing phase III studies. Valeant’s (VRX) Taribavirin (previously known as Viramidine) is in advanced clinical development.
http://www.zacks.com/stock/news/19571/Anadys:+Too+Early+for+HCV+Drug
its counter part ANDS doing poorly
"The Chinese use two brush strokes to write the word 'crisis.' One brush stroke stands for
danger; the other for opportunity. In a crisis, be aware of the danger - but recognize the opportunity." -J. Kennedy
Discover What Traders Are Watching
Explore small cap ideas before they hit the headlines.
